The kidney failure that requires transplant and dialysis may double by 2030 from the current 2.5 million, mostly in emerging economies, said a study on global health.
Known as Renal replacement therapy (RRT), through either dialysis or renal transplantation, is a life-saving yet high-cost treatment for people with end-stage kidney failure, said the George Institute for Global Health in its study.
The number of people receiving RRT will go up from 2.618 million in 2010 to 5.439 million by 2030, it projected in the study.
“However, the number of people without access to RRT will remain substantial,” the study titled ‘Worldwide access to treatment for end-stage kidney disease: a systematic review’ said. It was published in the journal The Lancet.
Patients with chronic kidney disease (CKD) have significant increases in cardiovascular morbidity and mortality, hospitalisation rates and reduced quality of life, with little hope to reduce the increasing burden of disease.